Finance

Fundamentals in Focus for Aramark (ARMK)

Aramark (NYSE:ARMK) is an interesting stock at present. Now trading with a market value of 9.90B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this ARMK, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Aramark (NYSE:ARMK) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ARMK, the company currently has 145.48 million of cash on the books, which is offset by 79.57 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 10.5 billion in total assets, balanced by 8.24 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Aramark (ARMK) saw 345.69 million in free cash flow last quarter, representing a quarterly net change in cash of -1.47 million. Perhaps most importantly where cash movements are concerned, the company saw about 454.23 million in net operating cash flow.

Aramark (NYSE:ARMK) Revenue Growth Potential



As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 3.62 billion in total revenues. That represents a quarterly year/year change in revenues of 0.01 in sequential terms, the ARMK saw sales decline by -0.03.

But what about the bottom line? After all, that’s what really matters in the end. Aramark (ARMK) is intriguing when broken down to its core data. The cost of selling goods last quarter was 3.35 billion, yielding a gross basic income of 275.21 million. For shareholders, given the total diluted outstanding shares of 251.72 million, this means overall earnings per share of 0.28. Note, this compares with a consensus analyst forecast of 0.35 in earnings per share for its next fiscal quarterly report.

Is Aramark (NYSE:ARMK) Valuation Attractive




Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 2 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 18.37. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Aramark.

Previous ArticleNext Article

Related Post

What the Insider Data Suggests About RAIT Financia... Recent insider trends for RAIT Financial Trust (NYSE:RAS) have caught the attention of investors. Patters in insider activity can help analysts formul...
Analyzing the Insider Data for MicroVision, Inc. (... Recent insider trends for MicroVision, Inc. (NASDAQ:MVIS) have caught the attention of investors. Insider activity is often a strong indicator of futu...
Are Halozyme Therapeutics, Inc. (HALO)’s Rec... Recent insider trends for Halozyme Therapeutics, Inc. (NASDAQ:HALO) have caught the attention of investors. Analysts monitor insider data to understan...
Clovis Oncology, Inc. (CLVS) Just Flashed an Extre... Clovis Oncology, Inc. (NASDAQ:CLVS) gained 10.48% in yesterday’s session, going up from its prior closing price of $69.46 to $76.74. The price has fal...
Critical Comparison: Bellicum Pharmaceuticals, Inc... Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) and Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) are the two most active stocks in the Biotechnology ind...

Leave a Reply

Your email address will not be published. Required fields are marked *